Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deep...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Osumi, Hiroki, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2015
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532210/
https://ncbi.nlm.nih.gov/pubmed/26273206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S87101
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars